Business Description
Auxilium Pharmaceuticals Inc
ISIN : US05334D1072
Description
Auxilium Pharmaceuticals, Inc., incorporated in the state of Delaware in July 1999. The Company is a specialty biopharmaceutical company which develops and markets products for specialist audiences. The Company now have a portfolio of 12 approved products, including one product with two indications. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy ("TRT") product, STENDRA (avanafil), an oral erectile dysfunction ("ED") therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the leading vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum or "CCH") for the treatment of Peyronie's disease ("PD" or "Peyronie's") and XIAFLEX for the treatment of Dupuytren's contracture ("DC" or "Dupuytren's"). We also have programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite, Striant, a buccal TRT, XIAFLEX for the treatment of PD in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy which was launched in the U.S. in January 2014 and is the first and only FDA-approved non-surgical treatment for PD. Approximately 75% of the Company's product shipments are to only three wholesalers: Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation. The Company faces competition from competitors in North America, Europe and elsewhere from pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.69 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.59 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.1 | |||||
| 3-Year EBITDA Growth Rate | -36.8 | |||||
| 3-Year EPS without NRI Growth Rate | -30 | |||||
| 3-Year FCF Growth Rate | -29.2 | |||||
| 3-Year Book Growth Rate | 36.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 0.99 | |||||
| Days Inventory | 162.63 | |||||
| Days Sales Outstanding | 73.47 | |||||
| Days Payable | 81.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.96 | |||||
| Operating Margin % | -27.33 | |||||
| Net Margin % | -36.62 | |||||
| FCF Margin % | -14 | |||||
| ROE % | -68.63 | |||||
| ROA % | -12.88 | |||||
| ROIC % | -15.93 | |||||
| ROC (Joel Greenblatt) % | -313.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 10.44 | |||||
| PS Ratio | 4.47 | |||||
| PB Ratio | 11.47 | |||||
| EV-to-Revenue | 5.59 | |||||
| Earnings Yield (Greenblatt) % | -4.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Auxilium Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 302.063 | ||
| EPS (TTM) (€) | -2.205 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 12.45 - 32.05 | ||
| Shares Outstanding (Mil) | 51.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Auxilium Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Auxilium Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Auxilium Pharmaceuticals Inc Frequently Asked Questions
What is Auxilium Pharmaceuticals Inc(FRA:FEJ)'s stock price today?
The current price of FRA:FEJ is €31.55. The 52 week high of FRA:FEJ is €32.05 and 52 week low is €12.45.
When is next earnings date of Auxilium Pharmaceuticals Inc(FRA:FEJ)?
The next earnings date of Auxilium Pharmaceuticals Inc(FRA:FEJ) is .
Does Auxilium Pharmaceuticals Inc(FRA:FEJ) pay dividends? If so, how much?
Auxilium Pharmaceuticals Inc(FRA:FEJ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers